Painful hidradenitis suppurativa

Clinical Journal of Pain

Volumn 26, Issue 5, 2010, Pages 435-444

  Smith, Howard S ^a   Chao, Jerome D ^a   Teitelbaum, Jason ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Hidradenitis suppurativa (HS); Infection; Keratinocytes nociception; Pain; TLR2

Indexed keywords

AMINOLEVULINIC ACID; BOTULINUM TOXIN A; CD209 ANTIGEN; CD68 ANTIGEN; CLINDAMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYPROTERONE ACETATE; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; ETANERCEPT; ETRETIN; ETRETINATE; FINASTERIDE; GLUCONATE ZINC; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; MINOCYCLINE; NICOTINE; PLACEBO; RETINOID; RIFAMPICIN; TETRACYCLINE; TOLL LIKE RECEPTOR 2;

ACNE; ADRENAL DISEASE; ALLODYNIA; ANTIBIOTIC THERAPY; APOCRINE GLAND; BILOPHILA WADSWORTHIA; BREAST HYPERTROPHY; CARBON DIOXIDE LASER; CHLAMYDIA TRACHOMATIS; CHRONIC PAIN; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CROHN DISEASE; CRYOTHERAPY; CUSHINGOID SYNDROME; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INFLAMMATION; KIDNEY DYSFUNCTION; KLEBSIELLA; LATENT TUBERCULOSIS; LIBIDO DISORDER; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; NOCICEPTION; PATHOGENESIS; PATIENT SATISFACTION; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; PROTEUS; QUALITY OF LIFE; RADIOFREQUENCY; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; SERUM SICKNESS; SKIN NODULE; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; SUPPURATIVE HIDRADENITIS; SURGICAL TECHNIQUE;

HIDRADENITIS SUPPURATIVA; HUMANS; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE;

EID: 77952374662     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181ceb80c     Document Type: Review

References (120)

1. Singer M, Cintron JR. Hidradenitis suppuratuva. Clinics Colon Rectal Surg. 2002;14:233-242.
2. Waters GS, Nelson H. Perianal hidradenits suppurativa. In: Beck DE, Wexner SD, eds. Fundamentals of Anorectal Surgery. 2th ed. London: WB Saunders Ltd; 1998;233-236.
3. Poli F, Jemec C, Revuz J. Clinical presentation. In: Jemec GBE, Revuz J, Leyden JJ, eds. Hidradenitis Suppurativa. Heidelberg, Germany: Springer; 2006;11-24.
4. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. New York: Mosby; 2004.
5. Revuz J. Medical treatments of hidradenitis supperativa: a new paradigm. Dermatology. 2007;215:95-96.
6. Jemec GBE. Medical treatment of hidradentitis suppurativa. Expert Opin Pharmacother. 2000;5:1767-1770.
7. Hurley H. Dermatologic Surgery, Principles and Practice. New York: Marcel Dekker; 1989.
8. Anderson MJ Jr, Dockerty MB. Perianal hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003;56:451-461.
9. Moroz A, Lee M-H, Clark J. Reflex sympathetic dystrophy with hidradenitis suppurativa exacerbation: a case report. Arch Phys Med Rehabil. 2001;82:412-414.
10. Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009:831-839.
11. von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurate. Br J Dermatol. 2001;144:809-813.
12. Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol. 1985;113:1-8.
13. Homma H. On apocrine sweat glands in white and Negro men and women. Bull Johns Hopkins Hops. 1926;38:365-371.
14. Paletta C, Jurkiewica MJ. Hidradenitis suppurativa. Clin Plast Surg. 1987;14:383-390.
15. Brown SC, Kazzazi N, Lord PH. Surgical treatment of perineal hidradenisit suppurativa with special reference to recognition of the perianal form. Br J Surg. 1986;73:978-980.
16. Wiltz O, Schoetz DJ Jr, Murray JJ, et al. Perianal hidradenitis suppurativa. The Lahey clinic experience. Dis Colon Rectum. 1990;33:731-734.
17. Naldi L. Epidemiology. In: Jemec GBE, Revuz J, Leyden JJ, eds. Hidradenitis Suppurativa. Heidelberg, Germany: Springer; 2006:58-64.
18. Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621-623.
19. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential percursor lesions. J Am Acad Sematol. 1996;35:191-194.
20. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596-601.
21. Jemec GBE, Heidenheim M, Nielsen NH. Hidradenitis suppurativa\ characteristics and consequences. Clin Exp Dermatol. 1996;21:419-423.
22. Simpson N. Effect of isotretinoin on the quality of life in patients with acne. Pharmacoeconomics. 1994;6:108-113.
23. Velpeau A. Dictionnaire de medicine, un repertoire general des Sciences Medicales sous la Rapport. Theorique et Pratique. Paris: Bechet Jeune; 1839.
24. Vernuil A. De l'hidrosadenite phlegmoneuse et des abces sudoripares. Arch Gen Med Paris. 1864;114:537-557.
25. Schiefferdecker P. Die Hautdrusen des Menschen, und der Saugetuere, ihre Biologishe und rassenanatomische Bedeutung Sowie die Muscularis Sexualis. Stuttgart: E. Schweizer; 1922.
26. Brunsting HA. Hidradenitis suppurativa: abcess of the apocrine sweat glands. Arch Derm Syphil. 1939;39:108-120.
27. Morgan WP, Hughes LE. The distribution, size and density of the apocrine glands in hidradenitis suppurativa. Br J Surg. 1979;66:853-856.
28. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539-561.
29. Larralde M, Abad ME, Munoz AS, et al. Childhood flexural comedones: a new entity. Arch Dermatol. 2007;143:909-911.
30. Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? Exper Dermatol. 2008;17:455-472.
31. Highet AS, Warren RE, Weekes AJ. Bacteriology and antibiotic treatment of perineal suppurative hidradenitis. Arch Dermatol. 1988;124:1047-1051.
32. Jacob SE, Kerdel FA. Biologic for hidradenitis suppurativa (Verneuil's disease in the Era of biologics). In: Jemec G, Revuz J, Leyden J, eds. Hidradenitis Suppurativa. Berlin: Springer Verlag; 2006;145-149.
33. Schauber J, Gallo RL. Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes. J Invest Dermatol. 2007;127:510-512.
34. Glaser R, Harder J, Lange H, et al. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol. 2005;6:57-64.
35. Tokura Y, Kobayashi M, Kabashima K. Epidermal chemo-kines and modulation by antihistamines, antibiotics and antifungals. Exp Dermatol. 2008;17:81-90.
36. Thornton JP, Abcarian H. Surgical treatment of perianal and perineal hidradenitis suppurativa. Dis Colon Rectum. 1978;21: 573-577.
37. Baron EJ, Curren M, Henderson G, et al. Bilophila wadsworthia isoloates from clinical specimens. J Clin Micro-biol. 1992;30:1882-1884.
38. Bendahan J, Paran H, Kolman S, et al. The possible role of Chlamydia trachomatis in perineal suppurative hidradenitis. Eur J Surg. 1992;158:213-215.
39. Jemec GB, Faber M, Gutschik E, et al. The bacteriology of hidradenitis suppurativa. Dermatol. 1996;193:203-206.
40. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
41. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169:1535-1541.
42. Hunger RE, Surovy AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and coloca-lizes with C-type lectin receptor. Br J Dermatol. 2008;158: 691-697.
43. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996;106:176-182.
44. Sellheyer K, Krahl D. What causes acne inversa (or hidradenitis suppurativa)?\The debate continues. J Cutan Pathol. 2008;35:795-797.
45. Hana A, Booken D, Henrich C, et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci. 2007; 80:2214-2220.
46. Harrison BJ, Kumar S, Read GF, et al. Hidradenitis suppurativa: evidence for an endocrine abnormality. Br J Surg. 1985;72:1002-1004.
47. Wolff K, Johnson RA, Suurmond D. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 5th ed. New York: McGraw-Hill; 2005.
48. Krbec AC. Current understanding and management of hidradenitis suppurativa. J Amer Acad Nurse Pract.2007;19: 228-234.
49. McAllister M. Hidradenitis suppurativa (acne inversa). In: Buttaro TM, Trybulski J, Bailey PP, et al. eds. Primary Care: A Collaborative Practice. 4th ed. St. Louis MO: Mosby; 2003:235-237.
50. Shah N. Hidradenitis suppurativa: a treatment challenge. Amer Family Physician. 2005;72:1547-1552.
51. Herrington S. Hidradenitis suppurativa. In: Dambro MR, eds. Griffith's 5 Minute Clinical Consult. 14th ed. Philadelphia: Lippincott Williams and Wilkins; 2007:570-572.
52. Mendonca CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154:977-978.
53. Clemmensen OJ. Topical treatment of hidradenitis suppur-ativa with clindamycin. Int J Dermatol. 1983;22:325-328.
54. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971-974.
55. Mortimer PS, Dawber RP, Gales MA, et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115: 263-268.
56. Sawers RS,Randall VA,Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cypro-terone acetate) and oestrogen therapy. Br J Dermatol. 1986; 115:269-274.
57. Kacar S, Akdogan M, Kosar Y, et al. Estrogen and cypro-terone acetate combination-induced autoimmune hepatitis. J Clin Gastroenterol. 2002;35:98-100.
58. Levesque H, Trivalle C, Manchon ND, et al. Fulminant hepatitis due to cyproterone acetate. Lancet. 1989;1:215-221.
59. Murphy BJ, Collins BJ. Severe hepatitis and liver failure induced by cyproterone acetate. Aust N Z J Med. 1996;26:724.
60. Eibs HG, Spielmann H, Hagele M. Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre-and postimplantation period of mouse embryos. I. Teratology. 1982;25:27-36.
61. Eibs HG, Spielmann H, Jacob-Muller U, et al. Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre-and postimplantation period of mouse embryos. II. Cyproterone acetate and medroxyproges-terone acetate treatment before implantation in vivo and in vitro. Teratology. 1982;25:291-299.
62. Farrell AM, Randall VA, Vafaee T, et al. Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol. 1999; 141:1138-1139.
63. Joseph MA, Jayaseelan E, Ganapathi B, et al. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat. 2005;16:75-78.
64. Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alphareductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41:555-563.
65. Brown CF, Gallup DG, Brown VM. Hidradenitis suppur-ativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988;158:12-15.
66. Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1984;11:500-502.
67. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73-76.
68. Chow ET, Mortimer PS. Successful treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br J Dermatol. 1992;126:415.
69. Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol. 1988;19: 355-356.
70. Scheman AJ. Nodulocystic acne and hidradenitis suppur-ativa treated with acitretin: a case report. Cutis. 2002;69: 287-288.
71. Hofer T, Itin PH. Acne inversa: a dapsone-sensitive derma-tosis. Hautarzt. 2001;52:989-992.
72. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211-213.
73. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289P-290P.
74. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339-350.
75. Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral cyclosporin. Clin Exp Dermatol. 2006;31:154-155.
76. Martinez F, Nos P, Benlloch S, et al. Hidradenitis suppur-ativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323-326.
77. Adams DR, Gordon KB, Devenyi AG, et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540-1542.
78. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97: 2155-2156.
79. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49: S275-S276.
80. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat. 2005;16:58-61.
81. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149: 1046-1049.
82. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008; 158:370-374.
83. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154: 726-729.
84. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis suppurativa with adalimumab. J Am Acad Dermatol. 2006;55:163-164.
85. Giamarellos-Bourboulis EJ, Pelekanou A, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567-572.
86. Sauder DN, Mamelak AJ. Understanding the new clinical landscape for psoriasis: a comparative review of biologics. J Cutan Med Surg. 2004;8:205-212.
87. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther. 2003;25:2487-2505.
88. Williams JD, Griffiths CE. Cytokine blocking agents in dermatology. Clin Exp Dermatol. 2002;27:585-590.
89. Maalouf E, Faye O, Poli F, et al. Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with inflix-imab. Ann Dermatol Venereol. 2006;133:473-474.
90. Frohlich D, Baaske D, Glatzel M. Radiotherapy of hidrade-nitis suppurativa\still valid today? Strahlenther Onkol. 2000; 176:286-289.
91. Gold M, Bridges TM, Bradshaw VL, et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol. 2004;3:S32-S35.
92. Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol. 2005;152:803-804.
93. O'Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116:1575-1576.
94. Sharon-Guidetti A, Ziv Y, Kummer E, et al. Granulocyte macrophage colony-stimulating factor for perianal hidrade-nitis suppurativa: report of a case. Dis Colon Rectum. 2006; 49:682-684.
95. Bong JL, Shalders K, Saihan E. Treatment of persistent painful nodules of hidradenitis suppurativa with cryotherapy. Clin Exp Dermatol. 2003;28:241-244.
96. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27: 528-529.
97. Brocard A, Knol AC, Khammari A, Dreno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. a pilot study. Dermatology. 2007;214:325-327.
98. Chvapil M, Stankova L, Zukoski C IV, et al. Inhibition of some functions of polymorphonuclear leukocytes by in vitro zinc. J Lab Clin Med. 1997;89:135-146.
99. Gueniche A, Viac J, Lizard G, et al. Protective effect of zinc on keratinocyte activation markers induced by interferon or nickel. Acta Derm Venereol. 1995;75:19-23.
100. Aksakal AB, Adisen E. Hidradenitis suppurativa: importance of early treatment; efficient treatment with electrosurgery. Dermatol Surg. 2008;34:228-231.
101. Iwasaki J, Marra DE, Fincher EF, et al. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device. Dermatol Surg. 2008;34:114-117.
102. Sadick N, Sorhaindo L. The radiofrequency frontier: a review of radiofrequency and combined radiofrequency pulsed-light technology in aesthetic medicine. Facial Plast Surg. 2005;21: 131-138.
103. 2 laser stripping-secondary intention technique. Br J Dermatol. 1994;131:551-556.
104. Madan V, Hindle E, Hussain W, et al. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol. 2008;159: 1309-1314.
105. Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2002;47:280-285.
106. Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009:1188-1198.
107. Ritz JP, Runkel N, Haier J, et al. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis.1998;13:164-168.
108. Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther. 2004;17:50-54.
109. Jemec GBE. The symptomatology of hidradenitis suppurativa in women. Br J Dermtol.1988;199:345-350.
110. Mitchell KM, Beck DE. Hidradenitis suppurativa. Surg Clin N Am. 2002;82:1187-1197.
111. Watson JD. Hidradenitis suppurativa-a clinical review. Br J Plast Surg. 1985;38:567-569.
112. Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppuritiva: a study of 106 cases. Surgeon. 2005;3:23-26.
113. Tanaka A, Hatoko M, Tada H, et al. Experience with surgical treatment of hidradenitis suppurativa. Ann Plast Surg. 2001; 47:636-642.
114. Weyandt G. Surgical management of acne inversa. Hautarzt. 2005;56:1033-1039.
115. Parks RW, Parks TG. Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl. 1997;79:83-89.
116. Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed). 1987;294:487-489.
117. Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg. 2000;26:638-643.
118. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppur-ativa: pathogenesis and management. Br J Plast Surg. 2003; 56:451-461.
119. Kagan RJ, Yakuboff KP, Warren P, et al. Surgical treatment of hidradentitis suppurativa: a 10-year experience. Surgery. 2005;138:734-740.
120. Bordier-Lamy F, Palot JP, Vitry F, et al. Surgical treatment of hidradenitis suppurativa: a retrospective study of 93 cases. Ann Dermatol Venereol. 2008;135:373-379.